Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs
The DOI matches its Crossref record; 253 of the 253 references it cites were found in a registry or an index.
Abstract
Highly potent, but poorly water-soluble, drug candidates are common outcomes of contemporary drug discovery programmes and present a number of challenges to drug development - most notably, the issue of reduced systemic exposure after oral administration. However, it is increasingly apparent that formulations containing natural and/or synthetic lipids present a viable means for enhancing the oral bioavailability of some poorly water-soluble, highly lipophilic drugs. This Review details the mechanisms by which lipids and lipidic excipients affect the oral absorption of lipophilic drugs and provides a perspective on the possible future applications of lipid-based delivery systems. Particular emphasis has been placed on the capacity of lipids to enhance drug solubilization in the intestinal milieu, recruit intestinal lymphatic drug transport (and thereby reduce first-pass drug metabolism) and alter enterocyte-based drug transport and disposition.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Conventional absorption and bioavailability assessments, and the body-weight regressions built upon them, implicitly assume the portal route and seldom quantify the lymphatic contribution, even though, for suitable compounds, it can represent a substantial fraction of systemic exposure [29,30].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [29]
In the citing paper
“This route becomes quantitatively relevant only for compounds that combine high lipophilicity with appreciable long-chain triglyceride solubility, for which a log P greater than 5 and a lipid solubility above approximately 50 mg/g are commonly cited as approximate thresholds [29,30].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [29]
In the citing paper
“Because lymphatic delivery reaches the systemic circulation while bypassing hepatic first-pass metabolism, it can materially increase the oral bioavailability of affected compounds and lower their apparent first-pass loss in a manner that a body-weight regression of systemic clearance or volume cannot anticipate [28,29,30].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [29]
In the citing paper
“For highly lipophilic drugs, a fraction of the absorbed dose can bypass the portal circulation entirely and reach the systemic circulation via the intestinal lymphatics, associated with triglyceride-rich lipoproteins (chylomicrons) assembled within the enterocyte [28,29].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [29]
In the citing paper
“The extent of transport is highly sensitive to prandial state and to the type and quantity of co-administered lipid, which differ across preclinical study designs and between the fasted conditions typical of first-in-human protocols and the fed conditions under which lymphatic transport is greatest [29,30].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [29]
Citations
Cites
Arzneimittelforschung: Erstanwendung am Menschen in der Phase I
Miletzki, B., & Gleiter, C. H. (2005) · Bundesgesundheitsblatt Gesundheitsforsch.Gesundheitsschutz · doi:10.1007/s00103-005-1024-7 · Cited by 9,355
Drug-like properties and the causes of poor solubility and poor permeability
Lipinski, C. A. (2000) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/s1056-8719(00)00107-6 · Cited by 3,734 · cited 1×
“This is especially the case when potent, but highly lipophilic, drug candidates arise from complex chemical scaffolds and multiple high-throughput activity screen”
BackgroundNuclear Receptors and Lipid Physiology: Opening the X-Files
Chawla, A., Repa, J. J., Evans, R. M., & Mangelsdorf, D. J. (2001) · Science · doi:10.1126/science.294.5548.1866 · Cited by 2,085
Apolipoprotein E: Far More Than a Lipid Transport Protein
Mahley, R. W., & Rall, S. C. (2000) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev.genom.1.1.507 · Cited by 1,836
Berge, K. E., Tian, H., Graf, G. A., Yu, L., Grishin, N. V., Schultz, J., Kwiterovich, P., Shan, B., Barnes, R., & Hobbs, H. H. (2000) · Science · doi:10.1126/science.290.5497.1771 · Cited by 1,648
Niemann-Pick C1 Like 1 Protein Is Critical for Intestinal Cholesterol Absorption
Altmann, S. W., Davis, H. R., Zhu, L.-J., Yao, X., Hoos, L. M., Tetzloff, G., Iyer, S. P. N., Maguire, M., Golovko, A., Zeng, M., et al. (2004) · Science · doi:10.1126/science.1093131 · Cited by 1,577
Smit, J. J. M., Schinkel, A. H., Elferink, R. P. J. O., Groen, A. K., Wagenaar, E., van Deemter, L., Mol, C. A. A. M., Ottenhoff, R., van der Lugt, N. M. T., van Roon, M. A., et al. (1993) · Cell · doi:10.1016/0092-8674(93)90380-9 · Cited by 1,456
Wu, C.-Y., & Benet, L. Z. (2005) · Pharmaceutical Research · doi:10.1007/s11095-004-9004-4 · Cited by 1,401 · cited 1×
“In addition to the potential effect of lipidic excipients (primarily surfactants) on P-gp-mediated efflux, Benet and co-workers have recently suggested that high-fat meals could inhibit P-g”
BackgroundSelf-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs
Neslihan Gursoy, R., & Benita, S. (2004) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2004.02.001 · Cited by 1,358
Regulation of Absorption and ABC1-Mediated Efflux of Cholesterol by RXR Heterodimers
Repa, J. J., Turley, S. D., Lobaccaro, J.-M. A., Medina, J., Li, L., Lustig, K., Shan, B., Heyman, R. A., Dietschy, J. M., & Mangelsdorf, D. J. (2000) · Science · doi:10.1126/science.289.5484.1524 · Cited by 1,301
Cited by
Items 101–200 of 1,003
Rotation-Facilitated Rapid Transport of Nanorods in Mucosal Tissues
Yu, M., Wang, J., Yang, Y., Zhu, C., Su, Q., Guo, S., Sun, J., Gan, Y., Shi, X., & Gao, H. (2016) · Nano Letters · doi:10.1021/acs.nanolett.6b03515 · Cited by 204
Narang, J., Khan, S., Baboota, S., Ali, J., Khan, S., & Narang, R. (2015) · International Journal of Pharmaceutical Investigation · doi:10.4103/2230-973x.167661 · Cited by 202
“[18] The lipophilic drugs after oral administration are absorbed and then diffuse across the intestinal enterocytes, where they combine with enterocyte lipoproteins.”
Influence of lipid type on gastrointestinal fate of oil-in-water emulsions: In vitro digestion study
Zhang, R., Zhang, Z., Zhang, H., Decker, E. A., & McClements, D. J. (2015) · Food Research International · doi:10.1016/j.foodres.2015.05.014 · Cited by 202
Biodegradable Core–Shell Carriers for Simultaneous Encapsulation of Synergistic Actives
Windbergs, M., Zhao, Y., Heyman, J., & Weitz, D. A. (2013) · Journal of the American Chemical Society · doi:10.1021/ja401422r · Cited by 199
On the role of bile salts in the digestion of emulsified lipids
Sarkar, A., Ye, A., & Singh, H. (2016) · Food Hydrocolloids · doi:10.1016/j.foodhyd.2016.03.018 · Cited by 196
Amorphous formulations for dissolution and bioavailability enhancement of poorly soluble APIs
Kanaujia, P., Poovizhi, P., Ng, W. K., & Tan, R. B. H. (2015) · Powder Technology · doi:10.1016/j.powtec.2015.05.012 · Cited by 194
Rehman, F. U., Shah, K. U., Shah, S. U., Khan, I. U., Khan, G. M., & Khan, A. (2017) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2016.1218462 · Cited by 190
“Their mechanism of enhancing bioavailability includes extended retention time in stomach, changes in physical barrier [15,16], changes in biochemical barrier [17,18], improved solubilization [19], decreased drug metabolism [18,20], and stimulation of lymphatic transport [21].”
BackgroundThe Potential of Exosomes From Cow Milk for Oral Delivery
Betker, J. L., Angle, B. M., Graner, M. W., & Anchordoquy, T. J. (2019) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2018.11.022 · Cited by 189
Oral Bioavailability: Issues and Solutions via Nanoformulations
Pathak, K., & Raghuvanshi, S. (2015) · Clinical Pharmacokinetics · doi:10.1007/s40262-015-0242-x · Cited by 188
“The most interesting mechanism of enhanced bioavailability is improvement of absorption through enhancement of gastrointestinal solubilization, thus overcoming physiological and biological barriers [129, 130].”
BackgroundRecent updates on bioaccessibility of phytonutrients
Thakur, N., Raigond, P., Singh, Y., Mishra, T., Singh, B., Lal, M. K., & Dutt, S. (2020) · Trends in Food Science & Technology · doi:10.1016/j.tifs.2020.01.019 · Cited by 187
Mucoadhesive carriers for oral drug delivery
Kumar, R., Islam, T., & Nurunnabi, M. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.09.024 · Cited by 187
O′Sullivan, C. M., Davidovich-Pinhas, M., Wright, A. J., Barbut, S., & Marangoni, A. G. (2017) · Food & Function · doi:10.1039/c6fo01805j · Cited by 186
DLL4 promotes continuous adult intestinal lacteal regeneration and dietary fat transport
Bernier-Latmani, J., Cisarovsky, C., Demir, C. S., Bruand, M., Jaquet, M., Davanture, S., Ragusa, S., Siegert, S., Dormond, O., Benedito, R., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci82045 · Cited by 185
“Further studies of such mechanisms may be of use for delivery of oral drugs, and the ability to shunt the route of orally administered drugs to either the lymphatic or blood system would be a major advance in drug delivery technology (74).”
BackgroundLi, Y., Zheng, J., Xiao, H., & McClements, D. J. (2012) · Food Hydrocolloids · doi:10.1016/j.foodhyd.2011.08.017 · Cited by 185
Hu, M., Li, Y., Decker, E. A., & McClements, D. J. (2010) · Food Hydrocolloids · doi:10.1016/j.foodhyd.2010.03.010 · Cited by 184
Rahman, M. A., Hussain, A., Hussain, M. S., Mirza, M. A., & Iqbal, Z. (2013) · Drug Development and Industrial Pharmacy · doi:10.3109/03639045.2012.660949 · Cited by 183
Production of pure drug nanocrystals and nano co-crystals by confinement methods
Fontana, F., Figueiredo, P., Zhang, P., Hirvonen, J. T., Liu, D., & Santos, H. A. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.05.002 · Cited by 183
Lipid excipients and delivery systems for pharmaceutical development: A regulatory perspective
Chen, M.-L. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.09.010 · Cited by 182
Drug nanocrystals – Versatile option for formulation of poorly soluble materials
Peltonen, L., & Hirvonen, J. J. (2017) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2017.12.005 · Cited by 182
Tang, C., Chen, H.-L., & Dong, J.-R. (2023) · Applied Sciences · doi:10.3390/app13031726 · Cited by 181
Self-nano-emulsifying drug delivery systems: an update of the biopharmaceutical aspects
Cherniakov, I., Domb, A. J., & Hoffman, A. (2015) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2015.999038 · Cited by 180
“Thus, most low-molecular-mass drugs are absorbed through the portal vein [19].”
BackgroundInfluentialShan, W., Zhu, X., Tao, W., Cui, Y., Liu, M., Wu, L., Li, L., Zheng, Y., & Huang, Y. (2016) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.6b08183 · Cited by 180
Nanovaccines: A game changing approach in the fight against infectious diseases
Priyanka, Abusalah, M. A. H., Chopra, H., Sharma, A., Mustafa, S. A., Choudhary, O. P., Sharma, M., Dhawan, M., Khosla, R., Loshali, A., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115597 · Cited by 179
Toniazzo, T., Berbel, I. F., Cho, S., Fávaro-Trindade, C. S., Moraes, I. C. F., & Pinho, S. C. (2014) · LWT · doi:10.1016/j.lwt.2014.05.021 · Cited by 176
Exploring oral nanoemulsions for bioavailability enhancement of poorly water-soluble drugs
Kotta, S., Khan, A. W., Pramod, K., Ansari, S. H., Sharma, R. K., & Ali, J. (2012) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2012.668523 · Cited by 175
“details the mechanisms by which lipids and lipidic excipients affect the oral absorption of lipophilic drug emphasized on the capacity of lipids to enhance drug solubilization in the intestinal milieu, recruit intestinal lymphatic drug transport and alter enterocyte-based drug transport and disposition [5].”
BackgroundCuiné, J. F., McEvoy, C. L., Charman, W. N., Pouton, C. W., Edwards, G. A., Benameur, H., & Porter, C. J. H. (2008) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21246 · Cited by 175
Self-citationControl of β-carotene bioaccessibility using starch-based filled hydrogels
Mun, S., Kim, Y.-R., & McClements, D. J. (2015) · Food Chemistry · doi:10.1016/j.foodchem.2014.10.053 · Cited by 175
Sivadasan, D., Sultan, M. H., Alqahtani, S. S., & Javed, S. (2023) · Biomedicines · doi:10.3390/biomedicines11041114 · Cited by 174
Bandyopadhyay, S., Katare, O. P., & Singh, B. (2012) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/j.colsurfb.2012.05.019 · Cited by 174
“This can be attributed to the shorter chain length and better fluidity of MCT’s, in consonance with the literature reports [2,31].”
BackgroundResultInfluentialNanobiomaterial-based vaccination immunotherapy of cancer
Chen, F., Wang, Y., Gao, J., Saeed, M., Li, T., Wang, W., & Yu, H. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.120709 · Cited by 175
Wu, W., He, W., Tan, Y., Tian, Z., Chen, L., Hu, F.-Q., & Wu, W. (2011) · International Journal of Nanomedicine · doi:10.2147/ijn.s17282 · Cited by 172
Chu, B.-S., Rich, G. T., Ridout, M. J., Faulks, R. M., Wickham, M. S. J., & Wilde, P. J. (2009) · Langmuir · doi:10.1021/la9008174 · Cited by 155
Improving oral bioavailability of nutraceuticals by engineered nanoparticle-based delivery systems
Yao, M., McClements, D. J., & Xiao, H. (2015) · Current Opinion in Food Science · doi:10.1016/j.cofs.2014.12.005 · Cited by 171
Mohsin, K., Long, M. A., & Pouton, C. W. (2009) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21659 · Cited by 171
Advances in nano-delivery systems for doxorubicin: an updated insight
Kanwal, U., Irfan Bukhari, N., Ovais, M., Abass, N., Hussain, K., & Raza, A. (2018) · Journal of Drug Targeting · doi:10.1080/1061186x.2017.1380655 · Cited by 155
“In addition, lipidbased nanoparticulate formulation showed altered biodistribution of drugs thereby, reducing the toxicity [76].”
BackgroundKoziolek, M., Grimm, M., Schneider, F., Jedamzik, P., Sager, M., Kühn, J.-P., Siegmund, W., & Weitschies, W. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.03.009 · Cited by 170
Shete, H. K., & Patravale, V. B. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2013.03.034 · Cited by 170
Leveraging Physiology for Precision Drug Delivery
Sun, W., Hu, Q., Ji, W., Wright, G., & Gu, Z. (2017) · Physiological Reviews · doi:10.1152/physrev.00015.2016 · Cited by 169
“Macroscale DDSs generally refer to drug delivery devices with at least one dimension greater than 1 mm in size (193, 342).”
BackgroundDrug nanocrystallisation within liposomes
Li, T., Cipolla, D., Rades, T., & Boyd, B. J. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.09.001 · Cited by 154
Tan, A., Rao, S., & Prestidge, C. A. (2013) · Pharmaceutical Research · doi:10.1007/s11095-013-1107-3 · Cited by 167
Diverse approaches for the enhancement of oral drug bioavailability
Fasinu, P., Pillay, V., Ndesendo, V. M. K., du Toit, L. C., & Choonara, Y. E. (2011) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.750 · Cited by 166
Lesmes, U., & McClements, D. J. (2009) · Trends in Food Science & Technology · doi:10.1016/j.tifs.2009.05.006 · Cited by 166
Controversies with self-emulsifying drug delivery system from pharmacokinetic point of view
Chatterjee, B., Hamed Almurisi, S., Ahmed Mahdi Dukhan, A., Mandal, U. K., & Sengupta, P. (2016) · Drug Delivery · doi:10.1080/10717544.2016.1214990 · Cited by 166
“, are among the most commonly used lipid component (Chambin & Jannin, 2005; Porter et al., 2007; Tang et al., 2007).”
BackgroundMethodTalegaonkar, S., & Bhattacharyya, A. (2019) · AAPS PharmSciTech · doi:10.1208/s12249-019-1337-8 · Cited by 165
“into the lymph vessels by exocytosis (83).”
Aungst, B. J. (2017) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2016.12.002 · Cited by 165
Sahbaz, Y., Williams, H. D., Nguyen, T.-H., Saunders, J., Ford, L., Charman, S. A., Scammells, P. J., & Porter, C. J. H. (2015) · Molecular Pharmaceutics · doi:10.1021/mp500790t · Cited by 165
Self-citationMcClements, D. J., Zou, L., Zhang, R., Salvia‐Trujillo, L., Kumosani, T., & Xiao, H. (2015) · Comprehensive Reviews in Food Science and Food Safety · doi:10.1111/1541-4337.12170 · Cited by 166
Villar, A. M. S., Naveros, B. C., Campmany, A. C. C., Trenchs, M. A., Rocabert, C. B., & Bellowa, L. H. (2012) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2012.04.001 · Cited by 164
Cho, H.-J., Salvia‐Trujillo, L., Kim, J., Park, Y., Xiao, H., & McClements, D. J. (2014) · Food Chemistry · doi:10.1016/j.foodchem.2014.01.084 · Cited by 164
High melting lipid based approach for drug delivery: Solid lipid nanoparticles
Kumar, S., & Randhawa, J. K. (2013) · Materials Science and Engineering C · doi:10.1016/j.msec.2013.01.037 · Cited by 163
Pye, C. R., Hewitt, W. M., Schwochert, J., Haddad, T. D., Townsend, C. E., Etienne, L., Lao, Y., Limberakis, C., Furukawa, A., Mathiowetz, A. M., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01483 · Cited by 153
Direct visualization of dispersed lipid bicontinuous cubic phases by cryo-electron tomography
Demurtas, D., Guichard, P., Martiel, I., Mezzenga, R., Hébert, C., & Sagalowicz, L. (2015) · Nature Communications · doi:10.1038/ncomms9915 · Cited by 162
Anby, M. U., Williams, H. D., McIntosh, M., Benameur, H., Edwards, G. A., Pouton, C. W., & Porter, C. J. H. (2012) · Molecular Pharmaceutics · doi:10.1021/mp300164u · Cited by 155
Self-citationOral and transdermal drug delivery systems: role of lipid-based lyotropic liquid crystals
Rajabalaya, R., Musa, M. N., Kifli, N., & David, S. R. N. (2017) · Drug Design Development and Therapy · doi:10.2147/dddt.s103505 · Cited by 162
“59 Mixed micelle formation plays an important role in the solubilization, transport and absorption of nonpolar bioactive components.”
Lipids and polymers in pharmaceutical technology: Lifelong companions
Siepmann, J., Faham, A., Clas, S., Boyd, B. J., Jannin, V., Bernkop‐Schnürch, A., Zhao, H., Lecommandoux, S., Evans, J. C., Allen, C. J., et al. (2019) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2018.12.080 · Cited by 163
“However, highly lipophilic drugs with a defined set of physicochemical properties, and in the presence of certain lipids, may also take the less dominant route of entering the bloodstream via the lymphatic system (Porter et al., 2007).”
BackgroundPinheiro, A. C., Coimbra, M. A., & Vicente, A. A. (2016) · Food Hydrocolloids · doi:10.1016/j.foodhyd.2015.07.025 · Cited by 160
Nanoemulsion delivery systems for enhanced efficacy of antimicrobials and essential oils
Garcia, C. R., Malik, M. H., Biswas, S., Tam, V. H., Rumbaugh, K. P., Li, W., & Liu, X. (2022) · Biomaterials Science · doi:10.1039/d1bm01537k · Cited by 136
Zhang, Z., Gao, F., Bu, H., Xiao, J., & Li, Y. (2012) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2011.08.016 · Cited by 159
Lipid-Based Nanocarrier System for the Effective Delivery of Nutraceuticals
Subramanian, P. (2021) · Molecules · doi:10.3390/molecules26185510 · Cited by 159
“[16] reported three main mechanisms by which lipophilic excipients enhance the absorption:”
BackgroundEffects of Diet on Acne and Its Response to Treatment
Baldwin, H., & Tan, J. (2021) · American Journal of Clinical Dermatology · doi:10.1007/s40257-020-00542-y · Cited by 158
Encapsulation of phenolic compounds within nano/microemulsion systems: A review
Garavand, F., Jalali‐Jivan, M., Assadpour, E., & Jafari, S. M. (2021) · Food Chemistry · doi:10.1016/j.foodchem.2021.130376 · Cited by 157
Safety concerns over the use of intestinal permeation enhancers: A mini-review
McCartney, F., Gleeson, J. P., & Brayden, D. J. (2016) · Tissue Barriers · doi:10.1080/21688370.2016.1176822 · Cited by 156
“Bile salts are naturally occurring in the small intestine, at concentrations up to 8mM in the fasted state and 18mM in the fed state, and can form mixed micelles with lecithin, fatty acids and cholesterol.(37,38) The NOD formulation is an enteric coated nanoparticle consisting of insulin and other components, one of w…”
BackgroundDitzinger, F., Price, D. J., Ilie, A.-R., Koehl, N. J., Janković, S., Τσακιρίδου, Γ., Aleandri, S., Kalantzi, L., Holm, R., Nair, A., et al. (2019) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12984 · Cited by 156
Parrott, N. J., Lukacova, V., Fraczkiewicz, G., & Bolger, M. B. (2009) · The AAPS Journal · doi:10.1208/s12248-008-9079-7 · Cited by 155
“Although the accuracy of this assumption was uncertain and measurements of human bile salt concentrations in different intestinal regions are limited and variable (35), we found that the profile of regional bile salt concentrations obtained was in good agreement with measured regional concentrations of bile acids in t…”
BackgroundKleberg, K., Jacobsen, J. B., & Müllertz, A. (2010) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.2010.01023.x · Cited by 154
“Adjacent to the enterocytes a pH gradient, or a yet unknown mechanism, is believed to cause a disintegration of the mixed micelles, thereby liberating and making the drug available for absorption.([3,4]) Recently, knowledge on composition of intestinal fluids has increased.”
BackgroundClarysse, S., Tack, J. F., Lammert, F., Duchateau, G. S. M. J. E., Reppas, C. I., & Augustijns, P. (2008) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21502 · Cited by 153
Chen, J., Zheng, J., McClements, D. J., & Xiao, H. (2014) · Food Chemistry · doi:10.1016/j.foodchem.2014.03.003 · Cited by 152
Williams, H. D., Sahbaz, Y., Ford, L., Nguyen, T., Scammells, P. J., & Porter, C. J. H. (2013) · Chemical Communications · doi:10.1039/c3cc48650h · Cited by 152
Self-citationWang, D., Jiang, Q., Dong, Z., Meng, T., Hu, F., Wang, J., & Yuan, H. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.115130 · Cited by 153
Excipient Nanoemulsions for Improving Oral Bioavailability of Bioactives
Salvia‐Trujillo, L., Martín‐Belloso, O., & McClements, D. J. (2016) · Nanomaterials · doi:10.3390/nano6010017 · Cited by 151
“The co-ingestion of a lipid source has been shown to improve the bioaccessibility of many hydrophobic bioactives by increasing their solubility in GIT fluids [2,34,35].”
BackgroundLipid nanoparticles: A challenging approach for oral delivery of BCS Class-II drugs
Poovi, G., & Narayanasamy, D. (2018) · Future Journal of Pharmaceutical Sciences · doi:10.1016/j.fjps.2018.04.001 · Cited by 151
Prajapati, H. N., Dalrymple, D. M., & Serajuddin, A. T. M. (2011) · Pharmaceutical Research · doi:10.1007/s11095-011-0541-3 · Cited by 150
“(8), a rational basis for the selection of lipid-based excipients is ‘elusive’ and the prediction of in vivo performance of these excipients is poor.”
BackgroundWhere are all the anthelmintics? Challenges and opportunities on the path to new anthelmintics
Nixon, S. A., Welz, C., Woods, D. J., Costa, L. M., Zamanian, M., & Martin, R. J. (2020) · International Journal for Parasitology Drugs and Drug Resistance · doi:10.1016/j.ijpddr.2020.07.001 · Cited by 150
Ravi, P. R., Aditya, N., Kathuria, H., Malekar, S., & Vats, R. (2014) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2013.12.015 · Cited by 148
“Lipid nanoparticles reach lymphatic system either by direct endocytosis/transcytosis uptake by membranous epithelial cells (M-cells) covering Payer’s patches in intestine or by partitioning into triglyceride-rich lipoprotein particles that are secreted into intestinal lymph [27].”
BackgroundCell-Penetrating Protein/Corrole Nanoparticles
Soll, M., Goswami, T. K., Chen, Q., Saltsman, I., Teo, R. D., Shahgholi, M., Lim, P. P., Bilio, A. J. D., Cohen, S., Termini, J. S., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-38592-w · Cited by 148
Potentials and challenges in self-nanoemulsifying drug delivery systems
Khan, A. W., Kotta, S., Ansari, S. H., Sharma, R. K., & Ali, J. (2012) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2012.719870 · Cited by 146
“Highly potent but poorly watersoluble drug candidates are a common outcome of contemporary drug discovery programs and present several challenges to drug development, most notably, the issue of reduced systemic exposure after oral administration [78].”
BackgroundMiller, J. M., Beig, A., Carr, R. A., Webster, G. K., & Dahan, A. (2012) · Molecular Pharmaceutics · doi:10.1021/mp200460u · Cited by 134
Lai, J., Chen, J., Lü, Y., Sun, J., Hu, F., Yin, Z., & Wu, W. (2009) · AAPS PharmSciTech · doi:10.1208/s12249-009-9292-4 · Cited by 146
“In fact, cubic nanoparticle is one kind of the secondary vehicles (micelles, mixed micelles, cubic nanoparticles, and vesicular carriers) formed after the digestion of lipids in the small intestine, which plays important roles in absorption enhancement of hydrophobic drugs (19).”
BackgroundAdvances in the design of fasted state simulating intestinal fluids: FaSSIF-V3
Fuchs, A., Leigh, M. L. S., Kloefer, B., & Dressman, J. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.05.015 · Cited by 145
Thomas, N., Holm, R., Garmer, M., Karlsson, J. J., Müllertz, A., & Rades, T. (2013) · The AAPS Journal · doi:10.1208/s12248-012-9433-7 · Cited by 144
Oral delivery system prolongs blood circulation of docetaxel nanocapsules via lymphatic absorption
Attili-Qadri, S., Karra, N., Nemirovski, A., Schwob, O., Talmon, Y., Nassar, T., & Benita, S. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1313839110 · Cited by 143
“Therefore, the lipoproteinated NCs are exocytosed from the enterocyte into the lamina propria like chylomicrons with access to the systemic circulation, through preferential uptake into the mesenteric lymphatic system (17).”
Solid self emulsifying drug delivery system: Superior mode for oral delivery of hydrophobic cargos
Maji, I., Mahajan, S., Sriram, A., Medtiya, P., Vasave, R., Khatri, D. K., Kumar, R., Singh, S. B., Madan, J., & Singh, P. K. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.08.013 · Cited by 144
The effect of curcumin and its nanoformulation on adjuvant-induced arthritis in rats
Cai, H., Zheng, Z., Sun, Y., Liu, Z., Zhang, M., & Li, C. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s90147 · Cited by 142
“30,31 Moreover, the presence of Solutol ® HS15, which is used as an emulsifier in the Ns formulation, can enable the drug to transport across the epithelial cell layer in intestine by maintaining the solubilization of poorly soluble drugs and inhibiting P-glycoprotein and CYP450.”
Beg, S., Sandhu, P. S., Batra, R. S., Khurana, R. K., & Singh, B. (2014) · Drug Delivery · doi:10.3109/10717544.2014.900154 · Cited by 142
“Lipidbased nanostructured drug delivery systems have shown immense promise in enhancing the oral bioavailability of such drugs not only by circumventing the issues of solubility, but also helps in eliminating the aforesaid hiccups of low oral bioavailability (Porter et al., 2007, 2008).”
BackgroundWilliams, H. D., Anby, M. U., Sassene, P., Kleberg, K., Bakala-N’Goma, J.-C., Calderone, M., Jannin, V., Igonin, A., Partheil, A., Marchaud, D., et al. (2012) · Molecular Pharmaceutics · doi:10.1021/mp300331z · Cited by 127
Self-citationApostolou, M., Assi, S. A., Fatokun, A. A., & Khan, I. (2021) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2021.04.012 · Cited by 142
Abdalla, A., Klein, S., & Mäder, K. (2008) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2008.09.006 · Cited by 142
“The change in lipid composition, induced by digestion, plays a major role in the solubilization capacity and consequently the absorption of co-administered drugs (Kossena et al., 2005; Porter et al., 2004, 2007).”
BackgroundLiu, W., Ye, A., Liu, C., Liu, W., & Singh, H. (2012) · Food Research International · doi:10.1016/j.foodres.2012.04.017 · Cited by 141
Controlled Release Systems Containing Solid Dispersions: Strategies and Mechanisms
Tran, P. H. L., Tran, T. T. D., Park, J.-B., & Lee, B. (2011) · Pharmaceutical Research · doi:10.1007/s11095-011-0449-y · Cited by 140
“Therefore, physicochemical properties of the lipidic materials should be determined because it could explain the reason why paraffin wax is excreted in the feces, whereas glycerides, due to less hydrophobicity, are digested by gastric and pancreatic lipase and co-lipase (80), or sucrose esters can be enzymatically hyd…”
BackgroundDevraj, R., Williams, H. D., Warren, D. B., Müllertz, A., Porter, C. J. H., & Pouton, C. W. (2012) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2012.11.024 · Cited by 140
Self-citationTransitions in the internal structure of lipid droplets during fat digestion
Salentinig, S., Sagalowicz, L., Leser, M. E., Tedeschi, C., & Glatter, O. (2010) · Soft Matter · doi:10.1039/c0sm00491j · Cited by 140
Uttreja, P., Karnik, I., Youssef, A. A. A., Narala, N., Elkanayati, R. M., Baisa, S., Alshammari, N. D., Banda, S., Vemula, S. K., & Repka, M. A. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17010063 · Cited by 140
Beg, S., Jena, S. S., Patra, C. N., Rizwan, M., Swain, S., Sruti, J., Rao, M. E. B., & Singh, B. (2012) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2012.06.031 · Cited by 137
Introduction to computational oral absorption simulation
Sugano, K. (2009) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425250902835506 · Cited by 129
“The items with asterisks are possible misconceptions if one uses the default functions b × : Poor predictability, ∆ : Marginal predictability, ○ : Reasonable predictability (e.g., with in 2 fold error with 70% probability), : Excellent predictability. c SEDDS, solid dispersion, nano API particle, controlled release, e…”
BackgroundInfluentialLi, C., Zhang, Su, Feng, Long, & Chen (2012) · International Journal of Nanomedicine · doi:10.2147/ijn.s38043 · Cited by 135
“…on liposome vesicle–micelle phase transition and carrier-mediated transmembrane absorption conferred by the ultradeformability of FLs. 6,21,22 In this study, a positive effect by FLs on the poorly water-soluble curcumin was observed, but the unstable structure of the FLs necessitated…”
Postprandial Changes in Solubilizing Capacity of Human Intestinal Fluids for BCS Class II Drugs
Clarysse, S., Psachoulias, D., Brouwers, J., Tack, J. F., Annaert, P., Duchateau, G. S. M. J. E., Reppas, C. I., & Augustijns, P. (2009) · Pharmaceutical Research · doi:10.1007/s11095-009-9857-7 · Cited by 134
“For each drug, solubility in FaSSIF (1), FeSSIF ( 2 ) and FeSSIF v2 (3) is indicated by broken lines.”
BackgroundSingh, G., & Pai, R. S. (2014) · Drug Delivery · doi:10.3109/10717544.2014.885616 · Cited by 133
“Studies have shown that the type of absorption pathway and subsequent transportation of drug is drastically influenced by the long-chain triglycerides (LCTs) (Porter et al., 2007; Bandyopadhyay et al., 2012).”
BackgroundWilliams, H. D., Trevaskis, N. L., Yeap, Y. Y., Anby, M. U., Pouton, C. W., & Porter, C. J. H. (2013) · Pharmaceutical Research · doi:10.1007/s11095-013-1126-0 · Cited by 133
Self-citationRecent approaches of lipid-based delivery system for lymphatic targeting via oral route
Chaudhary, S., Garg, T., Murthy, R. S. R., Rath, G., & Goyal, A. K. (2014) · Journal of drug targeting · doi:10.3109/1061186x.2014.950664 · Cited by 132
“chylomicrons and then transported to Golgi apparatus and finally exocytosis by enterocytes and enters into lacteals or lymphatic system [18].”
BackgroundDesign of Foods with Bioactive Lipids for Improved Health
Chen, B., McClements, D. J., & Decker, E. A. (2012) · Annual Review of Food Science and Technology · doi:10.1146/annurev-food-032112-135808 · Cited by 132
Metadata
- Authors
- Porter, C. J. H., Trevaskis, N. L., & Charman, W. N.
- Affiliations
- Monash University (AU)
- Corresponding author
- Porter, Christopher J. H.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2007-03
- Volume
- 6
- Issue
- 3
- Pages
- 231-248
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2069235788
- Cited by
- 1,824
- References
- 253
- Citations by year
- 2026: 88 · 2025: 87 · 2024: 67 · 2023: 89 · 2022: 119 · 2021: 108 · 2020: 140 · 2019: 101 · 2018: 117 · 2017: 121 · 2016: 125 · 2015: 119 · 2014: 120 · 2013: 128 · 2012: 94
- FWCI
- 4.11
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Drug Solubulity and Delivery Systems
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- lipid-based drug delivery, oral bioavailability, lipophilic drugs, poorly water-soluble drugs, lipid excipients, first-pass metabolism, lipid-based formulations
- MeSH terms
- Administration, Oral, Animals, Pharmaceutical Preparations, Excipients, Humans, Intestinal Absorption, Lipids, Drug Design, Drug Delivery Systems, Hydrophobic and Hydrophilic Interactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.